Anti-human transferrin receptor antibody that passes through blood-brain barrier

US9994641B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9994641-B2
Application numberUS-201415107839-A
CountryUS
Kind codeB2
Filing dateDec 24, 2014
Priority dateDec 25, 2013
Publication dateJun 12, 2018
Grant dateJun 12, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Disclosed are a novel anti-human transferrin receptor antibody comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 6 and 7 that can pass through the blood-brain barrier, a fusion protein comprising a protein necessary to be brought into function in the central nervous system and the antibody, and method of their production. The fusion protein comprises amino acid sequences of an anti-human transferrin receptor antibody that recognizes an amino acid sequence selected from the group consisting of SEQ ID NOs:1, 2, and 3, and of other protein that is bound thereto on the C-terminal side.

First claim

Opening claim text (preview).

The invention claimed is: 1. A single-chain anti-human transferrin receptor antibody comprising an amino acid sequence selected from the group consisting of SEQ ID Nos: 4, 5, 6, and 7. 2. A DNA sequence encoding the antibody according to claim 1 . 3. A fusion protein comprising the antibody according to claim 1 and another protein bound thereto on the C-terminal side. 4. The fusion protein according to claim 3 wherein the another protein is bound to the C-terminal side of the antibody by a linker sequence consisting of 3-50 amino acids. 5. The fusion protein according to claim 3 , wherein said another protein is a lysosomal enzyme. 6. The fusion protein according to claim 5 , wherein the lysosomal enzyme is human iduronate 2-sulfatase. 7. A DNA sequence encoding the fusion protein according to claim 3 . 8. A mammalian expression vector comprising the DNA sequence according to claim 7 . 9. A mammalian cell transformed with the mammalian expression vector according to claim 8 . 10. The cell according to claim 9 , wherein the mammalian cell is a CHO cell.

Assignees

Inventors

Classifications

  • Iduronate-2-sulfatase (3.1.6.13) · CPC title

  • from primates, e.g. man · CPC title

  • against CD71 · CPC title

  • Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

  • Single chain antibody (scFv) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9994641B2 cover?
Disclosed are a novel anti-human transferrin receptor antibody comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 6 and 7 that can pass through the blood-brain barrier, a fusion protein comprising a protein necessary to be brought into function in the central nervous system and the antibody, and method of their production. The fusion protein comprises amin…
Who is the assignee on this patent?
Japan Chem Res
What technology area does this patent fall under?
Primary CPC classification C07K16/2881. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jun 12 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).